Due to lack of HPV vaccination program, the diagnosed incident cases of cervical cancer in urban China are expected to increase at an annual growth rate (AGR) of 1.90% between 2020­ and 2030. China is followed by the US (0.78%), and the UK (0.34%), finds GlobalData, a leading data and analytics company.

However, diagnosed incident cases of cervical cancer in the eight major markets (8MM*) combined is expected to increase from 0.11 million cases in 2020 to 0.12 million in 2030, at an AGR of 1.27%.

GlobalData’s latest report, ‘Cervical Cancer: Epidemiology Forecast to 2030’, notes that the major drivers for the spike  in the diagnosed incident cases of cervical cancer in urban China is attributable to the shortage of HPV vaccination program due to high prices of imported vaccines, and the coverage of cervical cancer screening remains low.

Suneedh Manthri, Project Manager of Epidemiology at GlobalData, comments: “All women are at risk for cervical cancer. It occurs most often in women aged 30 years and older. Almost all cervical cancer cases (99%) are linked to infection with HPV, an extremely common virus transmitted through sexual contact. HPV vaccination and cervical cancer screening are highly effective and cost-effective in the prevention of cervical cancer in women. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.”

*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and urban China